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Background: Peripheral arterial disease (PAD) affects millions of Americans and leads to critical limb ischemia (CLI)
in the most severe cases. Investigators have demonstrated the utility of hydrogen sulfide for restoring perfusion in
rodent models of chronic ischemia. We sought to determine the minimum effective dose (MED) of sulfide necessary to
restore perfusion in the rat hindlimb, to assess the persistence of limb perfusion after cessation of treatment, and to
compare perfusion measurements between laser doppler and ultrasound methods.
Methods: In 3 separate experiments, sodium sulfide (1.0, 0.5, or 0.25 mg/kg twice daily for 14 days, 0.25 mg/kg twice
daily for 7 days, 0.5 mg/kg once daily for 7 days, or 0.25 mg/kg twice daily for 3 days) or vehicle was administered after
left femoral artery ligation and transection. Hindlimb perfusion was assessed by laser doppler flowmetry and contrast
enhanced ultrasound over the duration of each study, and cellular proliferation and vascular density were assessed by
immunohistochemical means in the initial experiment.
Results: Intravenous sodium sulfide at 0.25, 0.5, or 1.0 mg/kg twice daily for 2 weeks significantly enhanced the recovery
of blood flow to the ischemic hindlimb by 7 days. The enhancement of blood flow with 1.0 mg/kg dosing was
coincident with an increase in cellular proliferation and vascular density in the ischemic tissue. In a final experiment,
i.v. administration of sodium sulfide at 0.5 mg/kg once daily for 7 days or 0.25 mg/kg twice daily for 7 days significantly
elevated blood flow and skeletal muscle perfusion in the ischemic hindlimb, whereas 0.25 mg/kg twice daily for 3 days
had no effect. This enhancement of blood flow appeared long lived, as blood flow remained elevated 3 weeks after
cessation of treatment.
Conclusions: These data, together with other published observations, demonstrate the efficacy of hydrogen sulfide in
restoring perfusion to chronically ischemic tissue and establish a minimum efficacious dose in the rat hindlimb model.Background
Peripheral arterial disease (PAD) is characterized by a
narrowing of the arteries in peripheral vessels caused by
atherosclerotic plaque formation, resulting in decreased
blood flow to distal appendages. This disorder affects 8
to 12 million Americans and represents a significant fi-
nancial health care burden that will rise concomitantly
with the rates of obesity and diabetes [1]. Critical limb
ischemia (CLI), characterized by pain at rest, ulcerations,
and/or gangrene in the extremity, is considered an end* Correspondence: ctoombs@faradaypharma.com
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article, unless otherwise stated.stage of PAD, with the majority of these patients under-
going revascularization (bypass or angioplasty) or ampu-
tation as long as they can tolerate surgery [2,3].
Currently, there is no established nonsurgical treatment
regimen for CLI patients.
Hydrogen sulfide (H2S) plays a number of important
roles in cardiovascular physiology as a regulator of inflam-
mation, angiogenesis, vessel tone, and redox potential
[4-6]. It has also been shown to be protective in animal
models of cardiovascular disease including heart failure
[7-9], hypertension [10,11], atherosclerosis [12,13], and is-
chemia reperfusion injury in multiple organs and tissues
[14,15]. Mechanistically, sulfide is thought to mediated Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and signaling molecule, sulfide is thought to modulate
cellular function via reversible cysteine s-sulfhydration of
a number of enzymes, transcription factors, and cytoskel-
etal elements [16-18]. Another purported cytoprotective
mechanism stems from observations that sulfide at lower
concentrations can reversibly reduce the oxygen affinity of
cytochrome c oxidase, effectively dampening cellular res-
piration [19,20]. The nucleophilic nature of H2S is also
thought to contribute to its observed efficacy via the at-
tenuation of oxidative stress and reactive oxygen species
(ROS) signaling [21].
Therapeutic angiogenesis refers to the pharmacologic in-
duction of neovascularization to restore blood flow and
oxygenation in ischemic tissue, and published observations
suggest hydrogen sulfide could be such a pharmacophore.
H2S stimulates endothelial cell migration, proliferation, and
tube formation in vitro, and has been shown to stimulate
vascular growth in the chicken chorioallantoic membrane
and into matrigel plugs implanted in vivo in mice [5,22].
Furthermore, hydrogen sulfide has been shown to stimulate
vascular growth in ischemic heart tissue and improve car-
diac function in rodent models of heart failure [8,23]. The
molecular mechanisms underlying these effects are being
investigated, and evidence suggests that H2S enhances ni-
tric oxide production and bioavailability [24,25], increases
HIF-1α mediated gene expression (including VEGF and its
receptors) [24,26], and can activate VEGFR2 directly via re-
duction of a vicinal disulfide bond [27].
To date, several investigators have demonstrated the
capacity of hydrogen sulfide to revascularize and restore
blood flow to skeletal muscle in rodent models of hind-
limb ischemia (HLI). Wang and colleagues used fluores-
cent microspheres to assess the effect of NaHS on rat
hindlimb perfusion, and Bir et al. used laser doppler
flowmetry to demonstrate the beneficial effect of Na2S
on perfusion of the mouse hindlimb [24,28]. Both stud-
ies provided evidence suggesting that H2S mediates
these proangiogenic effects via the upregulation of VEGF
signaling. In the current study, we sought to determine a
minimum dose and schedule of parenteral hydrogen sul-
fide sufficient to restore perfusion in the rat hindlimb.
Utilizing contrast enhanced ultrasound to corroborate
laser doppler flowmetry results, we demonstrate here
that a twice daily intravenous infusion of 0.25 mg/kg so-
dium sulfide over as few as 7 days was sufficient to sig-
nificantly enhance perfusion in the ischemic hindlimb.
Moreover, the effect on perfusion persisted several weeks
after cessation of treatment.
Methods
Animals
Male CD rats, 350–450 g with jugular vein catheters
(JVC), were purchased from Charles River (Wilmington,MA). All experiments were approved by the internal
Ethical Committee for Animal Care and Use. All animals
were singly housed and allowed to acclimate in house
for at least 48 hours prior to study entry. The facility
was kept at a temperature of 21°C, humidity of 45-55%,
under a 12 hour light/dark cycle. Animals had access to
food and water ad libitum.
Surgical model
Under 1.5% isoflurane, animal fur was removed from the
distal hind limbs using depilatory cream, and blood flow
was measured as described below. An incision was made
in the left groin, and the femoral artery was carefully dis-
sected away from the femoral vein, femoral nerve, and
surrounding fascia. The femoral artery was ligated at
two points with silk suture just distal to the inguinal
ligament, and the vessel was then transected between
the two ligation points. The incision in the groin was
stapled closed, and hind limb blood flow was measured
again as described below.
Laser doppler flowmetry
A laser doppler flow meter (Product# ML191, ADInstru-
ments, Colorado Springs, CO) was used in conjunction
with either a miniature surface flow probe (Product#
MSP300XP, ADInstruments, Colorado Springs, CO) or a
fine needle flow probe (Product# MNP110XP, ADInstru-
ments, Colorado Springs, CO) to measure hind limb
blood flow. Blood flow was recorded and analyzed using
a PowerLab 8/30 (Product# ML870/P, Colorado Springs,
CO) with LabChart software, and a heat lamp was used
to maintain core body temperature while all blood flow
measurements were obtained. While under 1.5 % isoflur-
ane, flow measurements were taken from the proximal,
medial, and distal portions of each calf twice, for a total of
6 measurements per calf that were averaged to give a
single value. Blood flow in the ischemic (left) limb was
normalized to blood flow in the nonischemic (right) limb.
Contrast enhanced ultrasound measurements of hindlimb
perfusion
A Vevo 770 high-resolution ultrasound imaging system
(VisualSonics, Toronto, Ontario, Canada) equipped with
a 15–45 MHz RMV scanhead (Model# RMV707B,
VisualSonics, Toronto, Ontario, Canada) was used to
visualize the gastrocnemius and measure perfusion
within it. While under 1.5% isoflurane, a lateral section
of each gastrocnemius parallel to the fibula was visual-
ized. Once a satisfactory image was obtained, 150 μL of
a contrast microbubble solution containing 3.0 x 108
microbubbles were given as a bolus via the jugular vein
catheter, and the change in contrast visualized within each
gastrocnemius muscle was used to indicate perfusion in
the ischemic hindlimb relative to the nonischemic limb.
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core temperature of each animal over the course of
measurements.
Immunohistochemical assessment of vascular density and
cellular proliferation
Upon completion of the experimental protocol, each
animal was euthanized by exsanguination under 3.0%
isoflurane anesthesia. An incision was then made in the
left ventricle, and 10% buffered neutral formalin was
pushed through the lower torso via the abdominal aorta
just proximal to the iliac bifurcation. The left (ischemic)
and right (nonischemic) gastrocnemius muscles were
then excised and placed in 10% buffered neutral forma-
lin, at which point they were taken to the pathology de-
partment at the University of Washington for paraffin
embedding, sectioning, and staining.
Six short axis slices of each muscle were embedded
into paraffin blocks. For vascular density determination,
three sections from each block were stained for CD-31
(PECAM-1), an endothelial specific antigen, and coun-
terstained with hematoxylin. Digital images of 10 high
power fields within each section were obtained, and the
ratio of PECAM-1 positive vessels to myofibers was
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Figure 1 Na2S Enhances Blood Flow to the Ischemic Hind Limb. Panels A
and nonischemic hindlimbs, respectively, of rats before and after femoral a
hindlimb minutes after femoral artery ligation, expressed as the ratio of blo
limb (Panel B). Panel D illustrates the effect of i.v. administration of Na2S (1
vs Vehicle at respective time point by One Way ANOVA. Values are mean ±For determination of cellular proliferation, 3 sections
from each block were stained for Ki-67, a nuclear anti-
gen expressed only in proliferating cells. Digital images
of 10 high power fields within each section were ob-
tained, and the number of Ki-67 positive nuclei per high
power field were determined.
Data analysis
All data presented are expressed as the mean + SEM,
and all groups were compared using a one way ANOVA




In a pilot experiment, four animals were administered
sodium sulfide at 1.0 mg/kg (as a one minute i.v. infu-
sion) twice daily for 14 days, while another 4 animals re-
ceived vehicle (0.9% sodium chloride) at an identical
volume twice daily over the same time period. Figure 1
illustrates the effect of femoral artery ligation on hind-
limb blood flow measured by laser doppler flowmetry.
Panels A and B illustrate the absolute laser doppler
blood flow values obtained in the ischemic and nonis-
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and B are laser doppler blood flow values obtained from the ischemic
rtery ligation. Panel C illustrates changes in blood flow to the ischemic
od flow measured in the ischemic limb (Panel A) vs. the nonischemic
mg/kg, twice daily) on blood flow in the ischemic hindlimb. * p < 0.05
SEM.
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the left hindlimbs before and after left femoral artery
ligation in both treatment groups. In this graph, blood flow
in the ischemic limb is expressed as a ratio of flow in the
nonischemic (right) hind limb. Prior to the onset of ische-
mia, blood flow in both limbs was comparable (vehicle -
0.97 ± 0.041 vs 1.0 mg/kg sodium sulfide - 0.962 ± 0.033).
In the minutes following femoral artery transection, blood
flow was reduced in the ischemic limb to approximately
30% of the preischemic value (vehicle – 0.282 ± 0.023 vs
1.0 mg/kg Na2S – 0.290 ± 0.021). Together, these data
demonstrate that the decrease in relative blood flow after
the induction of ischemia was strictly due to a decrease in
blood flow in the ischemic limb; while blood flow in the
nonischemic limb was unaffected.
Panel D of Figure 1 illustrates the effect of i.v. admin-
istration of Na2S on blood flow recovery in the ischemic
hind limb. Sodium sulfide administered at 1.0 mg/kg
twice daily significantly elevated blood flow in the ische-
mic limb by day 7 compared to vehicle treatment and
was maintained through day 14. These data are consist-












































Ki-67, Nonischemic (Right) Limb, VehicleTreated
Ki-67, Nonischemic (Right) Limb, Na2S Treated
Figure 2 Na2S Enhances Cellular Proliferation and Vascular Density in the I
sections with Ki-67-positive nuclei (circled) from nonischemic and ischemic
representative images from sections of nonischemic and ischemic limbs, resp
comparing the average number of Ki-67 positive nuclei and PECAM-1 stained
vs Nonischemic of the same treatment group by one way ANOVA. Values arean enhancement of blood flow by day 7 in mice adminis-
tered sodium sulfide at 1.0 mg/kg twice daily [3].
After 14 days of treatment, the left and right gastro-
cnemius muscles from each animal were excised and
processed for immunohistochemical assessment of cellu-
lar proliferation and vascular density within the tissue.
Figure 2 demonstrates the effect of sulfide administra-
tion on vascular density and cellular proliferation within
the ischemic tissue. In animals receiving a 1.0 mg/kg
dose for 14 days, the number of Ki-67 positive nuclei
were significantly elevated in the ischemic limb (panels D
and E) compared to the nonischemic limb (panels C and
E); an effect which was not observed in vehicle treated
mice (panels A, B, and E). Similarly, the number of CD-31
positive cells were increased in the ischemic limbs of sul-
fide treated rats, whereas there was no effect on vascular
cell density observed in vehicle treated mice (Panel F).
Experiment 2
A second study addressed the questions of dose re-
sponse and minimal effective dosing of sulfide in the

























Ki-67, Ischemic (Left) Limb, VehicleTreated
Ki-67, Ischemic (Left) Limb, Na2S Treated
schemic Hind Limb. Panels A and B are representative images of
limbs, respectively, of vehicle treated rats. Panels C and D are
ectively, of 1.0 mg/kg Na2S treated animals. Panels E and F are graphs
vessels for gastrocnemius muscle across treatment groups. * p < 0.05
mean ± SEM.
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or vehicle twice daily for 14 days following the induction
of limb ischemia. Laser doppler measurements of blood
flow were taken pre- and post-ligation of the femoral ar-
tery on day 0, and then once daily on days 1, 3, 5, 7, 10,
12, and 14. All measurements were made with both the
fine needle flow probe used in the pilot study, as well as
a miniature surface probe. Hindlimb perfusion was also
measured on day 14 by contrast ultrasound.
Figure 3 illustrates the effects of twice daily adminis-
tration of sulfide at these 3 doses on the recovery of
blood flow in the ischemic hindlimb. Panels A and B dis-
play laser doppler measurements obtained with the mini-

























































































0.5 mg/kg Na2S (n=7)
1.0 mg/kg Na2S (n=7)
Vehicle (n=7)
0.25 mg/kg Na2S (n=7)
0.5 mg/kg Na2S (n=7)
1.0 mg/kg Na2S (n=7)
Vehicle (n=7)
0.25 mg/kg Na2S (n=7)






























































Figure 3 Twice Daily Administration of Na2S Enhances Ischemic
Limb Perfusion at Doses as Low as 0.25 mg/kg. Panels A and B
illustrate laser doppler blood flow measurements in the ischemic
hindlimbs of rats given vehicle or Na2S (0.25, 0.5, or 1.0 mg/kg)
i.v. twice daily for 14 days. Results in panels A and B were obtained
with a miniature surface probe and a fine needle probe, respectively.
* p < 0.05 vs Vehicle at respective time point by One Way ANOVA.
Values are mean ± SEM.These results demonstrate that sodium sulfide at 0.25, 0.5,
and 1.0 mg/kg doses significantly enhanced blood flow to
the ischemic hindlimb by day 7, and this elevation was
maintained through day 14. These results were consistent
with those of the initial pilot, and suggested a 4-fold lower
efficacious dose.
In an effort to corroborate these laser doppler flow re-
sults, contrast enhanced ultrasound measurements of
hindlimb skeletal muscle perfusion were used as an ad-
junct means of measurement. Figure 4 illustrates the im-
ages and data set obtained from a single animal on day 0
immediately following ischemic insult. Panels A and B
are images of sagittal sections of the right (nonischemic)
and left (ischemic) gastrocnemius muscles, respectively,
of the same rat obtained minutes after left femoral artery
ligation. Once satisfactory images were obtained, a solu-
tion of 3.0x108 microbubbles was administered as an i.v.
bolus, and the change in contrast over time was exam-
ined. Within a manually defined region of interest
(enclosed by the blue outline in panels A and B), the
change in contrast intensity was calculated for each
frame of captured video and used to create the scatter
plot shown in panel C. From the fitted curve of the scat-
ter plot, the plateau and the slope can be calculated. The
plateau represents the maximum change in contrast and
is an indicator of blood volume, while the slope indicates
the rate of change in contrast intensity and reflects the
rate of blood flow. Panels D and E are representative il-
lustrations of the changes in blood volume and flow rate,
respectively, in the ischemic hindlimb just minutes after
femoral artery ligation (generated from the curves in
panel C). Total blood volume in the ischemic gastrocne-
mius of the rodent was decreased to 42% of the volume
in the nonischemic limb, consistent with LD flow mea-
surements taken just after the induction of ischemia.
Panel E demonstrates a reduction in the rate of blood
flow in the ischemic gastrocnemius of greater than 90%
compared to the nonischemic muscle just after surgery.
Figure 5 shows day 14 contrast ultrasound measurements
of hindlimb perfusion from the same group of animals
from Figure 3. Panels A-D are representative plots of
contrast measurements taken from vehicle, 0.25 mg/kg,
0.5 mg/kg, or 1.0 mg/kg NaaS treated rats, respectively,
suggesting that sulfide treatment at all 3 doses restores
blood volume in the ischemic hindlimb by day 14. Panel E
illustrates these results, which paralleled those obtained
with both laser doppler flow probes on day 14 (Figures 3A
and B).
Experiment 3
A final experiment was designed to determine if the
changes in blood flow with Na2S treatment persisted
after treatment stopped, as well as to attempt to further






























































































Right (Nonischemic) Limb Left (Ischemic) LimbA B
Figure 4 Contrast Ultrasound Measurements of Hind Limb Perfusion. Panels A and B are images of the gastrocnemius muscles in the
nonischemic and ischemic limbs, respectively, from a single animal minutes after left femoral artery ligation. After microbubble injection, the
change in contrast over time can be measured over a manually selected region of interest (ROI) within the image (shown enclosed by a blue
line). Panel C is a scatter plot of the change in contrast intensity over time derived from the ROIs in panels A and B. Panels D and E demonstrate
the cumulative changes in contrast intensity and the rates of change in intensity, respectively, which are derived from the best fit curves for the
scatter plots in panel C.
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0.25 mg/kg sodium sulfide twice daily for 7 days (n = 8),
0.25 mg/kg twice daily for 3 days (n = 8), 0.5 mg/kg once
a day for 7 days (n = 8), or vehicle twice daily for 7 days
(n = 8). For this experiment, LD blood flow measure-
ments were made pre- and post- ligation on day 0, and
then on days 7, 14, and 28. Contrast ultrasound mea-
surements were made on days 14 and 28.
Figure 6 illustrates the results of laser doppler mea-
surements of blood flow from these animals. In animals
that were treated with sodium sulfide at 0.25 mg/kgtwice daily for 7 days or at 0.5 mg/kg once a day for
7 days, blood flow in the ischemic limb was significantly
elevated by day 7. The results of the former treatment
group are consistent with laser doppler results from the
previous experiment, and the results from rats adminis-
tered Na2S at 0.5 mg/kg suggest that multiple daily admin-
istrations are unnecessary. Furthermore, the elevation of
blood flow at day 7 was maintained through day 28 in
both treatment groups, suggesting that the positive effects
of sulfide administration were not transient. Blood flow in
















































































































































































Figure 5 Contrast Ultrasound Perfusion Measurements Corroborate Laser Doppler Measurements. Panels A-D are representative scatter plots of
changes in contrast in the ischemic and nonischemic hindlimbs of a single animal from vehicle, 0.25 mg/kg, 0.5 mg/kg, or 1.0 mg/kg Na2S
treated cohorts, respectively, after 14 days of treatment. Panel E is a comparison of the change in contrast intensity in the ischemic limbs
between treatment groups.
Langston and Toombs Medical Gas Research  (2015) 5:5 Page 7 of 10a day for 3 days was never significantly different from ve-
hicle treated animals at any time point.
Contrast ultrasound was again used as an alternative
means of assessing perfusion in the ischemic hindlimb,
this time taking measurements at both day 14 and day
28. Consistent with laser doppler blood flow results, so-
dium sulfide administered twice daily at 0.25 mg/kg or
once daily at 0.5 mg/kg for 7 days significantly elevated
the total blood volume delivered to ischemic skeletal
muscle. This effect was seen in both treatment groups at
day 14 (Figure 7A) and day 28 (Figure 7C). While there
was a positive impact on blood volume, there was no
significant effect on the rate of blood flow (Day 14 –
Figure 7B, Day 28 – Figure 7D).Discussion
In previous reports of the efficacy of sulfide in the hind-
limb model, investigators utilized extended treatment
periods. Wang et al. treated rats once daily for 4 weeks,
while Bir et al. treated mice twice daily for 2 weeks. In
the present study, we started with the dosing regimen
used by Bir et al. and incrementally decreased the dosing
concentration and frequency until we approached an
MED. In our hands, we find that sodium sulfide admin-
istered intravenously at 0.25 mg/kg twice daily, or at
0.5 mg/kg once daily, for 7 days was sufficient to restore
perfusion to ischemic skeletal muscle. Furthermore, this
MED was also shown to provide a prolonged effect that
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Figure 6 7 Day Administration of Na2S is Sufficient to Enhance
Blood Flow to the Ischemic Hind Limb, which Persists 3 Weeks After
Treatment is Stopped. This graph illustrates day 0, 7, 14, and 28 laser
doppler blood flow measurements from the ischemic hind limbs of
rats treated with either vehicle or Na2S at 0.25 mg/kg twice daily for
3 days, 0.25 mg/kg twice daily for 7 days, or 0.5 mg/kg once daily
for 7 days. * p < 0.05 vs Postligation within the same treatment




































































































































Figure 7 Corroboration of Laser Doppler Measurements with Ultrasound. P
volume and blood flow rate, respectively, at day 14 from the ischemic hind
daily for 3 days, 0.25 mg/kg twice daily for 7 days, or 0.5 mg/kg once daily
at day 28 from the same animals. * p < 0.05 vs Vehicle by One Way ANOVA
Langston and Toombs Medical Gas Research  (2015) 5:5 Page 8 of 10In considering techniques for measuring tissue perfu-
sion, intravenous injection of fluorescent microspheres is
a cost effective approach, but it is an end point measure-
ment; lacking the capacity for multiple measurements in
a single animal. Laser doppler flowmetry affords the
ability to noninvasively measure blood flow in the same
animal repeatedly. However, shallow penetration allows
only very superficial blood flow to be measured, and oc-
clusion of subdermal microvascular blood flow with the
probe itself is a concern with non-scanning probes like
those used in this study. We therefore used contrast en-
hanced ultrasound in conjunction with laser doppler
measurements. Ultrasound provides an actual image of
the tissue that perfusion is being measured in, offers a
much better depth of measurement, and circumvents is-
sues with superficial microvascular occlusion. Results of
contrast ultrasound perfusion measurements corrobo-
rated those using LD flowmetry.
Clinical trials of therapeutic angiogenesis for PAD and
CLI have focused on delivery of constructs encoding
genes for proangiogenic growth factors like VEGF, FGF,
and HGF or certain bone marrow derived progenitor cell
populations, with mixed results. The small size of hydro-




















































































































anels A and B are contrast ultrasound measurements of relative blood
limbs of rats treated with either vehicle or Na2S at 0.25 mg/kg twice
for 7 days. Panels C and D show relative blood volume and flow rate
. Values are mean ± SEM.
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can facilitate its delivery to ischemic tissue despite a di-
minished or absent blood flow. At physiologic pH (7.4),
sulfide exists predominantly as the more hydrophilic
hydrosulfide anion (HS−), which would be subject to
partitioning and is more sensitive to oxidation relative to
its fully protonated counterpart. Sulfide becomes in-
creasingly protonated as pH falls, reaching its pKa at 7.0,
and then exists predominantly as H2S gas at more acidic
pH. The acidification of ischemic tissue would only favor
sulfide protonation, which should facilitate its delivery
within ischemic tissue.
Conclusions
The results of this study corroborate findings from other
labs demonstrating that hydrogen sulfide enhances blood
flow and vascular density in the ischemic rat hindlimb
when administered at 0.5 and 1.0 mg/kg twice daily over
14 days. The minimum efficacious dose is either
0.25 mg/kg twice daily or 0.5 mg/kg once daily for 7 days.
Shortening the treatment window to 3 days was nonef-
fective. Furthermore, these effects appear to be long-
lived. These data, together with published results from a
number of other labs, lend further credence to the no-
tion that hydrogen sulfide can enhance the vascularity
and perfusion of ischemic tissue.
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